Protagen

The project aims to identify biomarkers for predicting response and adverse events in urothelial carcinoma patients receiving immunotherapy.

The parties will use machine learning to develop biomarker models for immunotherapy endpoints, including adverse effects, clinical response, and survival.

With a series of recent collaborations in hand, the company is leveraging its experience in autoimmune biomarkers to move into the immunoncology space.

Under the collaboration, they will use Protagen's SeroTag platform to test cancer immunotherapy patients for markers linked to immune-related adverse events.

The partners will use Protagen’s autoantibody measuring technology to identify biomarkers of patient response to cancer immunotherapies.

The company said that it can distinguish patients suffering from lupus from those with other autoimmune diseases using its antibody array platform.

The company has partnered with the German National Center for Tumor Diseases to identify biomarkers for predicting response to immunotherapy in melanoma patients.

The license allows Inova to include the BICD2 biomarker in its portfolio of connective tissue disease reagents aimed at the diagnosis of systemic sclerosis.

The company now offers three CE-marked autoantibody assays — for BICD2, Scl70, and CENP-B — that can be used for clinical management of the condition.

According to the company, some of the autoantibodies it has identified as disease markers appear to be directed against potentially interesting drug targets.

Pages

An artificial intelligence-based analysis suggests a third group of ancient hominins likely interbred with human ancestors, according to Popular Mechanics.

In Science this week: reduction in bee phylogenetic diversity, and more.

The New York Times Magazine looks into paleogenomics and how it is revising what's know about human history, but also possibly ignoring lessons learned by archaeologists.

The Economist reports on Synthorx's efforts to use expanded DNA bases they generated to develop a new cancer drug.